Almuthe Christine Hauer

Prof. Dr. Almuthe Christine Hauer

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CPChristian Prause
Christian Prause
TRThomas Richter
Thomas Richter
SKSibylle Koletzko
Sibylle Koletzko
HUH Holm Uhlig
H Holm Uhlig
AHAlmuthe Christine Hauer
Almuthe Christine Hauer
TMThomas Mothes
Thomas Mothes

26 February 2014 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
PKPeter I Kalmar
Peter I Kalmar
TPThomas Petnehazy
Thomas Petnehazy
UWUlrike Wießpeiner
Ulrike Wießpeiner
Meinrad BeerMeinrad Beer
Meinrad Beer
AHAlmuthe Christine Hauer
Almuthe Christine Hauer
MRMichael Riccabona
Michael Riccabona
Failure to thrive and hematochezia in children may be alarm signs warranting endoscopy. In contrast, vascular malformations of the small intestine are uncommon in this age group. We report on a female toddler in whom various imaging techniques revealed an unusually large segmental vascular malformation of the ileum as the cause of the child’s main clinical symptoms.

7 July 2025 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
AHAlmuthe Christine Hauer
Almuthe Christine Hauer
MSMutaz Sultan
Mutaz Sultan
ADAndy Darma
Andy Darma
EAEyad Altamimi
Eyad Altamimi
DSDaniela Elena Serban
Daniela Elena Serban
JAJorge Amil‐Dias
Jorge Amil‐Dias

14 February 2020 in Monatsschrift Kinderheilkunde
Verified
Journal Article
Open access
PDF file
AHAlmuthe Christine Hauer
Almuthe Christine Hauer
Zusammenfassung: Die Labordiagnostik hat sowohl im empfohlenen initialen „work up“ bei Verdacht auf eine chronisch entzündliche Darmerkrankung (CED) wie auch für das Monitoring des Krankheitsverlaufs und des Therapieansprechens einen klar umrissenen Stellenwert: Mithilfe der „Basislaborparameter“ wie z. B. Blutkörperchensenkungsgeschwindigkeit (BSG) können krankheitsspezifische Aktivitätsindizes erstellt werden, und neue serologische Marker (u. a. ANCA [„antineutrophil cytoplasmic antibodies“], ASCA [„anti-saccharomyces cerevisiaeantibodies“]) dienen der ergänzenden Differenzierung der CED-Entitäten. Derzeit dürfte das Stuhl-Calprotectin – als am weitreichendsten untersuchter fäkaler Inflammationsmarker – v. a. aufgrund der hohen Sensitivität initial und zur Einschätzung der Krankheitsaktivität der relativ beste Surrogatmarker sein. Nach wie vor ist aber die endoskopisch-histopathologische Evaluierung nicht nur für die Diagnose unabdingbar, sondern auch bezüglich des erklärten Therapieziels des „mucosal healing“, also im Rahmen der präzisen Verlaufsdokumentation. Der Entwicklung weniger invasiver „Biomarker“, die möglichst gut mit dem Schleimhautbefund korrelieren, kommt besondere Bedeutung zu, um die derzeit oft noch notwendige invasive Reevaluierung verringern zu helfen. Wie die Wertigkeit sowohl in der Routine etablierter, aber auch neuer, teils experimentell angewandter serologischer, fäkaler und funktioneller Laborparameter bzw. -tests einzuschätzen ist, und welche diagnostischen Methoden in Erprobung sind, wird im vorliegenden Beitrag erläutert.

17 August 2017 in Monatsschrift Kinderheilkunde
Verified
Journal Article
Closed access
PDF file
AHAlmuthe Christine Hauer
Almuthe Christine Hauer

6 May 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
RPRaffaela Miriam Planka
Raffaela Miriam Planka
AHAlmuthe Christine Hauer
Almuthe Christine Hauer
SBSebastian Bauchinger
Sebastian Bauchinger
BKBenno Kohlmaier
Benno Kohlmaier
Background: Due to dysbiosis, intestinal barrier dysfunction, and immunosuppressive therapy, pediatric inflammatory bowel disease (PIBD) patients are more susceptible to infections. However, data on bacterial gastrointestinal (GI) infections in this population are scarce, and no guidelines explicitly address immunosuppressive therapy management during such infections. This single-center study aims to address these knowledge gaps. Methods: A retrospective study of bacterial GI infections was conducted in PIBD patients aged 0–18 years, treated between 2011 and 2021 at the Department of Pediatrics and Adolescent Medicine, Medical University of Graz. Data to assess the study endpoints were extracted from the hospital information system. Results: A total of 139 PIBD patients were screened for bacterial GI infections. The mean follow-up time was 49 months (standard deviation ±33) and the total follow-up time amounted to approximately 473 person-years. Fourteen patients developed infections, with three experiencing them twice, resulting in 17 cases of infection. Most infections were caused by opportunistic bacteria, and 10 infections were treated with antibiotics (11 antibiotic prescriptions in total). At infection onset, 12 patients were on (combined) immunosuppressive therapy, including corticosteroids (3 patients), immunomodulators (9 patients), and/or biologics (3 patients). Six infections required escalation of immunosuppressive therapy due to increased PIBD activity. Hospitalization was required in five cases, and one Clostridioides difficile infection progressed to sepsis, necessitating intensive care unit admission. This corresponds to an incidence of three infections (95% confidence interval 1.75–4.80) and 0.2 severe infections per 100 person-years (95% confidence interval 0.01–1.11). Conclusions: The incidence of bacterial GI infections was 3 per 100 person-years (95% confidence interval: 1.75–4.80), with most cases being clinically mild. Clostridioides difficile was the most common pathogen. Immunosuppressive therapy was generally continued or intensified, when necessary, while antibiotic therapy was administered as indicated.